🚀 VC round data is live in beta, check it out!
Anavex Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Anavex Life Sciences and similar public comparables like Keros Therapeutics, Ever Supreme Bio Technology, Armata Pharmaceuticals, Upstream Bio and more.
Anavex Life Sciences Overview
About Anavex Life Sciences
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Founded
2004
HQ
Employees
34
Website
Sectors
Financials (FY)
EV
$288M
Anavex Life Sciences Financials
Anavex Life Sciences reported last fiscal year revenue of — and negative EBITDA of ($46M).
In the same fiscal year, Anavex Life Sciences generated ($46M) in EBITDA losses and had net loss of ($46M).
Revenue (LTM)
Anavex Life Sciences P&L
In the most recent fiscal year, Anavex Life Sciences reported revenue of — and EBITDA of ($46M).
Anavex Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($46M) | XXX | XXX | XXX |
| Net Profit | ($38M) | XXX | ($46M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Anavex Life Sciences Stock Performance
Anavex Life Sciences has current market cap of $420M, and enterprise value of $288M.
Market Cap Evolution
Anavex Life Sciences' stock price is $4.53.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $288M | $420M | 0.0% | XXX | XXX | XXX | $-0.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnavex Life Sciences Valuation Multiples
Anavex Life Sciences trades at (6.2x) EV/EBITDA.
EV / Revenue (LTM)
Anavex Life Sciences Financial Valuation Multiples
As of March 21, 2026, Anavex Life Sciences has market cap of $420M and EV of $288M.
Equity research analysts estimate Anavex Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anavex Life Sciences has a P/E ratio of (10.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $420M | XXX | $420M | XXX | XXX | XXX |
| EV (current) | $288M | XXX | $288M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (6.2x) | XXX | XXX | XXX |
| EV/EBIT | (6.7x) | XXX | (5.6x) | XXX | XXX | XXX |
| P/E | (10.9x) | XXX | (9.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Anavex Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Anavex Life Sciences Margins & Growth Rates
Anavex Life Sciences' revenue in the last fiscal year grew by —.
Anavex Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 6% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Anavex Life Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Keros Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ever Supreme Bio Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Upstream Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Immix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anavex Life Sciences M&A Activity
Anavex Life Sciences acquired XXX companies to date.
Last acquisition by Anavex Life Sciences was on XXXXXXXX, XXXXX. Anavex Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Anavex Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnavex Life Sciences Investment Activity
Anavex Life Sciences invested in XXX companies to date.
Anavex Life Sciences made its latest investment on XXXXXXXX, XXXXX. Anavex Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Anavex Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Anavex Life Sciences
| When was Anavex Life Sciences founded? | Anavex Life Sciences was founded in 2004. |
| Where is Anavex Life Sciences headquartered? | Anavex Life Sciences is headquartered in United States. |
| How many employees does Anavex Life Sciences have? | As of today, Anavex Life Sciences has over 34 employees. |
| Who is the CEO of Anavex Life Sciences? | Anavex Life Sciences' CEO is Christopher U. Missling. |
| Is Anavex Life Sciences publicly listed? | Yes, Anavex Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Anavex Life Sciences? | Anavex Life Sciences trades under AVXL ticker. |
| When did Anavex Life Sciences go public? | Anavex Life Sciences went public in 2006. |
| Who are competitors of Anavex Life Sciences? | Anavex Life Sciences main competitors are Keros Therapeutics, Ever Supreme Bio Technology, Armata Pharmaceuticals, Upstream Bio. |
| What is the current market cap of Anavex Life Sciences? | Anavex Life Sciences' current market cap is $420M. |
| Is Anavex Life Sciences profitable? | No, Anavex Life Sciences is not profitable. |
| What is the current net income of Anavex Life Sciences? | Anavex Life Sciences' last 12 months net income is ($38M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.